vs
Assertio Holdings, Inc.（ASRT）与LCNB CORP（LCNB）财务数据对比。点击上方公司名可切换其他公司
LCNB CORP的季度营收约是Assertio Holdings, Inc.的1.8倍（$23.9M vs $13.5M），LCNB CORP同比增速更快（5.1% vs -57.9%），过去两年LCNB CORP的营收复合增速更高（15.7% vs -35.4%）
Assertio Therapeutics是一家美国专业制药企业，主要聚焦神经病学、疼痛以及中枢神经系统疾病领域的产品销售与推广。公司前身Depomed成立于1995年，总部位于加利福尼亚州纽瓦克，拥有多款获美国FDA批准的产品，目前在纳斯达克上市。
LCNB集团是总部位于美国的金融控股公司，通过旗下附属国民银行开展业务，主要为俄亥俄州区域市场的个人消费者、中小企业及本地社区机构提供零售与商业银行产品、财富管理及保险相关服务。
ASRT vs LCNB — 直观对比
营收规模更大
LCNB
是对方的1.8倍
$13.5M
营收增速更快
LCNB
高出63.0%
-57.9%
两年增速更快
LCNB
近两年复合增速
-35.4%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $13.5M | $23.9M |
| 净利润 | — | $5.7M |
| 毛利率 | — | — |
| 营业利润率 | -86.7% | 29.2% |
| 净利率 | — | 23.7% |
| 营收同比 | -57.9% | 5.1% |
| 净利润同比 | — | -7.6% |
| 每股收益（稀释后） | $-4.54 | $0.40 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ASRTLCNB
| Q4 25 | $13.5M | $23.9M | ||
| Q3 25 | $49.5M | $23.8M | ||
| Q2 25 | $29.2M | $22.8M | ||
| Q1 25 | $26.5M | $21.5M | ||
| Q4 24 | $32.2M | $22.7M | ||
| Q3 24 | $29.2M | $21.4M | ||
| Q2 24 | $31.1M | $19.3M | ||
| Q1 24 | $32.4M | $17.8M |
净利润ASRTLCNB
| Q4 25 | — | $5.7M | ||
| Q3 25 | $11.4M | $6.9M | ||
| Q2 25 | $-16.4M | $5.9M | ||
| Q1 25 | $-13.5M | $4.6M | ||
| Q4 24 | — | $6.1M | ||
| Q3 24 | $-2.9M | $4.5M | ||
| Q2 24 | $-3.7M | $925.0K | ||
| Q1 24 | $-4.5M | $1.9M |
营业利润率ASRTLCNB
| Q4 25 | -86.7% | 29.2% | ||
| Q3 25 | 23.2% | 35.6% | ||
| Q2 25 | -27.5% | 31.6% | ||
| Q1 25 | -50.0% | 25.6% | ||
| Q4 24 | -41.9% | 32.9% | ||
| Q3 24 | -10.4% | 24.9% | ||
| Q2 24 | -11.6% | 4.9% | ||
| Q1 24 | -13.4% | 12.5% |
净利率ASRTLCNB
| Q4 25 | — | 23.7% | ||
| Q3 25 | 23.1% | 29.1% | ||
| Q2 25 | -56.0% | 26.0% | ||
| Q1 25 | -51.1% | 21.4% | ||
| Q4 24 | — | 27.0% | ||
| Q3 24 | -10.0% | 21.2% | ||
| Q2 24 | -11.8% | 4.8% | ||
| Q1 24 | -13.9% | 10.7% |
每股收益（稀释后）ASRTLCNB
| Q4 25 | $-4.54 | $0.40 | ||
| Q3 25 | $0.11 | $0.49 | ||
| Q2 25 | $-0.17 | $0.41 | ||
| Q1 25 | $-0.14 | $0.33 | ||
| Q4 24 | $-3.28 | $0.44 | ||
| Q3 24 | $-0.03 | $0.31 | ||
| Q2 24 | $-0.04 | $0.07 | ||
| Q1 24 | $-0.05 | $0.15 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $63.4M | $21.6M |
| 总债务越低越好 | — | $104.4M |
| 股东权益账面价值 | $94.0M | $273.9M |
| 总资产 | $267.0M | $2.2B |
| 负债/权益比越低杠杆越低 | — | 0.38× |
8季度趋势，按日历期对齐
现金及短期投资ASRTLCNB
| Q4 25 | $63.4M | $21.6M | ||
| Q3 25 | $93.4M | $35.9M | ||
| Q2 25 | $98.2M | $49.8M | ||
| Q1 25 | $87.3M | $37.7M | ||
| Q4 24 | $100.1M | $35.7M | ||
| Q3 24 | $88.6M | $39.4M | ||
| Q2 24 | $88.4M | $34.9M | ||
| Q1 24 | $80.7M | $33.0M |
总债务ASRTLCNB
| Q4 25 | — | $104.4M | ||
| Q3 25 | — | $104.7M | ||
| Q2 25 | — | $105.0M | ||
| Q1 25 | — | $104.6M | ||
| Q4 24 | — | $155.2M | ||
| Q3 24 | — | $155.7M | ||
| Q2 24 | — | $162.2M | ||
| Q1 24 | $38.6M | $162.6M |
股东权益ASRTLCNB
| Q4 25 | $94.0M | $273.9M | ||
| Q3 25 | $105.8M | $269.9M | ||
| Q2 25 | $93.3M | $263.5M | ||
| Q1 25 | $108.5M | $258.7M | ||
| Q4 24 | $121.1M | $253.0M | ||
| Q3 24 | $130.5M | $253.2M | ||
| Q2 24 | $132.2M | $245.2M | ||
| Q1 24 | $134.5M | $233.7M |
总资产ASRTLCNB
| Q4 25 | $267.0M | $2.2B | ||
| Q3 25 | $319.8M | $2.2B | ||
| Q2 25 | $273.8M | $2.3B | ||
| Q1 25 | $286.4M | $2.3B | ||
| Q4 24 | $284.7M | $2.3B | ||
| Q3 24 | $276.0M | $2.3B | ||
| Q2 24 | $279.4M | $2.4B | ||
| Q1 24 | $282.0M | $2.3B |
负债/权益比ASRTLCNB
| Q4 25 | — | 0.38× | ||
| Q3 25 | — | 0.39× | ||
| Q2 25 | — | 0.40× | ||
| Q1 25 | — | 0.40× | ||
| Q4 24 | — | 0.61× | ||
| Q3 24 | — | 0.61× | ||
| Q2 24 | — | 0.66× | ||
| Q1 24 | 0.29× | 0.70× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-30.0M | $34.4M |
| 自由现金流经营现金流 - 资本支出 | — | $33.4M |
| 自由现金流率自由现金流/营收 | — | 140.2% |
| 资本支出强度资本支出/营收 | — | 4.0% |
| 现金转化率经营现金流/净利润 | — | 6.08× |
| 过去12个月自由现金流最近4个季度 | — | $54.5M |
8季度趋势，按日历期对齐
经营现金流ASRTLCNB
| Q4 25 | $-30.0M | $34.4M | ||
| Q3 25 | $-4.8M | $14.0M | ||
| Q2 25 | $19.1M | $5.5M | ||
| Q1 25 | $-12.5M | $2.2M | ||
| Q4 24 | $11.5M | $93.2M | ||
| Q3 24 | $-35.0K | $11.9M | ||
| Q2 24 | $7.4M | $54.9M | ||
| Q1 24 | $7.5M | $-11.9M |
自由现金流ASRTLCNB
| Q4 25 | — | $33.4M | ||
| Q3 25 | — | $13.7M | ||
| Q2 25 | — | $5.2M | ||
| Q1 25 | — | $2.1M | ||
| Q4 24 | — | $89.4M | ||
| Q3 24 | — | $10.5M | ||
| Q2 24 | — | $53.8M | ||
| Q1 24 | — | $-12.8M |
自由现金流率ASRTLCNB
| Q4 25 | — | 140.2% | ||
| Q3 25 | — | 57.4% | ||
| Q2 25 | — | 23.0% | ||
| Q1 25 | — | 10.0% | ||
| Q4 24 | — | 394.0% | ||
| Q3 24 | — | 49.0% | ||
| Q2 24 | — | 278.6% | ||
| Q1 24 | — | -71.8% |
资本支出强度ASRTLCNB
| Q4 25 | — | 4.0% | ||
| Q3 25 | — | 1.3% | ||
| Q2 25 | — | 1.0% | ||
| Q1 25 | — | 0.3% | ||
| Q4 24 | — | 16.7% | ||
| Q3 24 | 0.0% | 6.7% | ||
| Q2 24 | — | 5.9% | ||
| Q1 24 | — | 4.8% |
现金转化率ASRTLCNB
| Q4 25 | — | 6.08× | ||
| Q3 25 | -0.42× | 2.02× | ||
| Q2 25 | — | 0.92× | ||
| Q1 25 | — | 0.48× | ||
| Q4 24 | — | 15.23× | ||
| Q3 24 | — | 2.63× | ||
| Q2 24 | — | 59.35× | ||
| Q1 24 | — | -6.24× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ASRT
| Products | $12.8M | 95% |
| Other | $719.0K | 5% |
LCNB
暂无分部数据
